Corrections

Correction to Lancet
Diabetes Endocrinol
2022; 10: 407–17
Battelino T, Bergenstal RM, Rodríguez A, Published Online
et al. Efficacy of once-weekly tirzepatide June 22, 2022
https://doi.org/10.1016/
versus once-daily insulin degludec S2213-8587(22)00169-3
on glycaemic control measured by
continuous glucose monitoring in adults
with type 2 diabetes (SURPASS-3 CGM):
a substudy of the randomised, open-label,
parallel-group, phase 3 SURPASS-3 trial.
Lancet Diabetes Endocrinol 2022;
10: 407–17—In this Article, the following
data were corrected due to rounding
errors: in table 1, mean age in the
tirzepatide 5 mg group should have
been 57·0 (SD 11·1) years; in paragraph
three of the Results section, time in
tight target range within a 24 h period
for patients given tirzepatide (pooled
10 mg and 15 mg groups) should have
been 73% (SE 2); in table 2, proportion
of time in tight target range at week
52 should have been 73% (SE 2) for the
tirzepatide group, time (min) under
change from baseline at week 24
heading should have been 538 (SE 51)
for the tirzepatide 5 mg group, and
proportion of time for estimated
treatment difference versus insulin
degludec at week 24 should have been
7% (–0·4 to 13) for the tirzepatide 5 mg
group; and, in figure 3 panel A, the
proportion of participants with time
in range at baseline in the tirzepatide
15 mg group should have been 49%.
These corrections have been made to
the online version as of June 22, 2022.

www.thelancet.com/diabetes-endocrinology Vol 10 August 2022 e8